API | fam-trastuzumab deruxtecan-nxki

fam-trastuzumab deruxtecan-nxki (Enhertu) Report issue

Biologics mAb ADC Approved ^FDA Fast Track ^FDA Accelerated Approval ^FDA

AACT ChEMBL

Active Ingredient History

NOW

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying the cell. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

rg-1512

trastuzumab deruxtecan

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA topoisomerase 1 (Homo sapiens) ^UniProt
- P-selectin (Homo sapiens) ^UniProt
- Receptor tyrosine-protein kinase erbB-2 (Homo sapiens) ^UniProt
- Receptor tyrosine-protein kinase erbB-2 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: deruxtecan
Black Box: No
Availability: Prescription Only
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$1734.3400 - $2261.3600

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ds-8201a | rg-1512

Organizations (51)

Research & Development (51)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (22)

Approved Indications (3)

Breast Neoplasms (approved 2019)

Carcinoma, Non-Small-Cell Lung (approved 2022)

Gastrointestinal Neoplasms (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (22)

Adenocarcinoma (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Biomarkers (Phase 1)

Brain Neoplasms (Phase 4)

Breast Neoplasms (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Transitional Cell (Phase 1)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 3)

Gastrointestinal Neoplasms (Phase 2)

Genes, erbB-2 (Phase 2)

Glioblastoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Osteosarcoma (Phase 2)

Radiotherapy (Phase 2)

Salivary Gland Neoplasms (Phase 1)

Stomach Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 69
# of Trial Organizations: 51

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue